Innate Pharma has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application to commence a Phase I trial of IPH4502 for solid tumours.

IPH4502 is a topoisomerase I inhibitor antibody-drug conjugate (ADC) targeting Nectin-4 solid tumours.

The Phase I study, set to commence in the next few months, is designed as an open-label, multicentre trial.

It will be conducted in two parts: part one dose escalation and part two dose optimisation.

The trial aims to evaluate the tolerability, safety and initial efficacy of IPH4502 when administered as a single agent.

Patients with advanced solid tumours known to express Nectin-4 will be enrolled in the study.

These include, but are not limited to, people with urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, and colorectal cancers.

Nectin-4 is a cell membrane adhesion protein that is overexpressed in several types of solid tumours such as urothelial, breast, oesophageal, lung, ovarian, and pancreatic cancers.

It is notably less expressed in normal tissues, making it a promising target for cancer therapy.

IPH4502 showed significant anti-tumour efficacy both in vitro and in vivo in non-clinical models.

Innate Pharma chief medical officer Dr Sonia Quaratino said: “We are thrilled to advance the IPH4502 programme, and the IND application acceptance is an important milestone for Innate, as this is our first ADC programme to enter the clinic.

“IPH4502 is a novel and differentiated Nectin-4 ADC that has the potential to provide a new therapeutic option for patients with a cancer expressing a wide range of Nectin-4. Through this Phase I study, we aim to advance the research on our ADC technology for the benefit of patients.”

"FDA grants IND clearance for Innate Pharma’s solid tumour trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

 

The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.